SCHEMBL6135735

SCHEMBL6135735

CCC(O)c1ccc(Br)cn1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.44
ESR1 P03372 4/20 0.39
ESR2 Q92731 4/20 0.39
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 1/20 0.38
RAB9A P51151 4/20 0.38
LMNA P02545 1/20 0.38
NPC1 O15118 1/20 0.36
ADRA2A P08913 2/20 0.36
ADRA2B P18089 2/20 0.36
ADRA2C P18825 2/20 0.36
PLAU P00749 1/20 0.36
FDPS P14324 1/20 0.35
S1PR4 O95977 2/20 0.35
S1PR3 Q99500 2/20 0.35
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29876671 1.00 GBA1 (0.44) GBA1ESR1ESR2KDM4EALDH1A1
SCHEMBL11962614 0.87 GBA1 (0.41) GBA1ESR1ESR2KDM4EALDH1A1
SCHEMBL4901498 0.84 KDM4E (0.38) GBA1KDM4EALDH1A1RAB9ANPC1
SCHEMBL12064587 0.83 GBA1 (0.37) GBA1ESR1ESR2KDM4EALDH1A1
SCHEMBL30931223 0.82 KDM4E (0.37) GBA1KDM4EALDH1A1RAB9ANPC1
SCHEMBL15856172 0.82 TAAR1 (0.39) GBA1KDM4EALDH1A1LMNAADRA2A
SCHEMBL29182976 0.82 KDM4E (0.37) GBA1KDM4EALDH1A1RAB9ANPC1
SCHEMBL15856223 0.82 KDM4E (0.37) GBA1KDM4EALDH1A1RAB9ANPC1
SCHEMBL20185086 0.82 KDM4E (0.37) GBA1KDM4EALDH1A1RAB9ANPC1
SCHEMBL30504098 0.82 KDM4E (0.37) GBA1KDM4EALDH1A1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240207263-A1 SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF SUZHOU ZANRONG PHARMA LIMITED (CN) 2024-06-27 US disclosed
EP-2760854-B1 IMIDAZOLE DERIVATIVES AS CYP17 INHIBITORS FOR THE TREATMENT OF CANCER ASANA BIOSCIENCES LLC (US) 2017-08-30 EP disclosed
EP-2760854-B1 IMIDAZOLE DERIVATIVES AS CYP17 INHIBITORS FOR THE TREATMENT OF CANCER ASANA BIOSCIENCES LLC (US) 2017-08-30 EP disclosed
US-9416144-B2 Benzoxazine oxazolidinone compound, preparation method and application thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2016-08-16 US disclosed
US-9199975-B2 Biaryl imidazole derivatives for regulating CYP17 ASANA BIOSCIENCES, LLC (US) 2015-12-01 US disclosed
US-9199975-B2 Biaryl imidazole derivatives for regulating CYP17 ASANA BIOSCIENCES, LLC (US) 2015-12-01 US disclosed
US-9199975-B2 Biaryl imidazole derivatives for regulating CYP17 ASANA BIOSCIENCES, LLC (US) 2015-12-01 US disclosed
US-20150336984-A1 BENZOXAZINE OXAZOLIDINONE COMPOUND, PREPARATION METHOD AND APPLICATION THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2015-11-26 US disclosed
US-20130085164-A1 Imidazole Derivatives ENDO PHARMACEUTICALS INC. (US) 2013-04-04 US disclosed
WO-2013049565-A1 IMIDAZOLE DERIVATIVES AS CYP17 INHIBITORS FOR THE TREATMENT OF CANCER ENDO PHARMACEUTICALS INC. (US) 2013-04-04 WO disclosed
US-20130085164-A1 Imidazole Derivatives ENDO PHARMACEUTICALS INC. (US) 2013-04-04 US disclosed
US-20130085164-A1 Imidazole Derivatives ENDO PHARMACEUTICALS INC. (US) 2013-04-04 US disclosed
US-20080021071-A1 3-{4-(Pyridin-3-Yl) Phenyl}-5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents ASTRAZENECA AB (SE) 2008-01-24 US disclosed
EP-1592419-A1 USE OF PHOSPHODIESTERASE-4 INHIBITORS AS ENHANCERS OF COGNITION Merck Frosst Canada & Co. (CA) 2005-11-09 EP disclosed
WO-2004047836-A1 USE OF PHOSPHODIESTERASE-4 INHIBITORS AS ENHANCERS OF COGNITION MERCK FROSST CANADA & CO. (CA) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150336984-A1 BENZOXAZINE OXAZOLIDINONE COMPOUND, PREPARATION METHOD AND APPLICATION THEREOF OXA1L, XDH, MYD88 GBA1 384/4885ESR1 3372/4885ESR2 3990/4885
US-20080021071-A1 3-{4-(Pyridin-3-Yl) Phenyl}-5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents MRPL21, ARG1, OXA1L GBA1 2698/4885ESR1 3620/4885ESR2 3271/4885
US-20240207263-A1 SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF ATM, CHEK2, CHEK1 GBA1 670/4885ESR1 3926/4885ESR2 3634/4885
US-20130085164-A1 Imidazole Derivatives CYP17A1, CYP2A7, CYP11B1 GBA1 1887/4885ESR1 624/4885ESR2 2127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.